Prostate Adenocarcinoma, TMPRSS2::ETV1 Fusion-Positive: Two Cases with Clinical and Molecular Characterization

被引：0
|
作者：
Bubar, R. [1 ]
Korentzelos, D. [1 ]
Wald, A. [1 ]
Tucker, J. [1 ]
Mohebnasab, M. [1 ]
机构：
[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
来源：
JOURNAL OF MOLECULAR DIAGNOSTICS | 2024年 / 26卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
ST130
引用
收藏
页码：S133 / S133
页数：1
相关论文
共 50 条
  • [31] Difference of genomic signatures and opportunities for targeted and immunotherapies in castrate resistant TMPRSS2:ERG fusion positive and TMPRSS2:ERG wild type refractory acinar (CRPC) and neuroendocrine prostate cancer (CRNEPC).
    Bratslavsky, Gennady
    Fisher, Hugh A. G.
    Byler, Timothy
    Jacob, Joseph M.
    Chung, Jon
    Elvin, Julia Andrea
    Vergilio, Jo-Anne
    Ramkissoon, Shakti
    Suh, James
    Severson, Eric Allan
    Daniel, Sugganth
    Ali, Siraj Mahamed
    Schrock, Alexa Betzig
    Miller, Vincent A.
    Stephens, Philip J.
    Gay, Laurie M.
    Kotula, Leszek
    Ross, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [32] miR-449a Repression Leads to Enhanced NOTCH Signaling in TMPRSS2:ERG Fusion Positive Prostate Cancer Cells
    Bauer, Simone
    Ratz, Leonie
    Heckmann-Noetzel, Doreen
    Kaczorowski, Adam
    Hohenfellner, Markus
    Kristiansen, Glen
    Duensing, Stefan
    Altevogt, Peter
    Klauck, Sabine M.
    Sueltmann, Holger
    CANCERS, 2021, 13 (05) : 1 - 18
  • [33] Differences in genomic signatures and opportunities for targeted and immunotherapy treatment between castrate-resistant TMPRSS2: ERG fusion-positive and -negative refractory acinar (CRPC) and neuroendocrine prostate cancer (CRNEPC).
    Kotula, Leszek
    Bratslavsky, Gennady
    Fisher, Hugh A. G.
    Byler, Timothy
    Corona, Robert John
    Jacob, Joseph
    Basnet, Alina
    Chung, Jon
    Elvin, Julia Andrea
    Vergilio, Jo-Anne
    Suh, James
    Ramkissoon, Shakti H.
    Daniel, Sugganth
    Severson, Eric Allan
    Schrock, Alexa Betzig
    Ali, Siraj Mahamed
    Miller, Vincent A.
    Gay, Laurie M.
    Ross, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] Association of SPINK1 Expression and TMPRSS2:ERG Fusion with Prognosis in Endocrine-Treated Prostate Cancer
    Leinonen, Katri A.
    Tolonen, Teemu T.
    Bracken, Hazel
    Stenman, Ulf-Hakan
    Tammela, Teuvo L. J.
    Saramaki, Outi R.
    Visakorpi, Tapio
    CLINICAL CANCER RESEARCH, 2010, 16 (10) : 2845 - 2851
  • [35] Androgens Induce Functional CXCR4 through ERG Factor Expression in TMPRSS2-ERG Fusion-Positive Prostate Cancer Cells
    Cai, Juan
    Kandagatla, Pridvi
    Singareddy, Rajareddy
    Kropinski, Anthony
    Sheng, Shijie
    Cher, Michael L.
    Chinni, Sreenivasa R.
    TRANSLATIONAL ONCOLOGY, 2010, 3 (03): : 195 - U58
  • [36] GENOMIC LANDSCAPE AND OPPORTUNITIES FOR TARGETED AND IMMUNOTHERAPIES IN PATIENTS WITH TMPRSS2:ERG FUSION POSITIVE VS. WILD TYPE CASTRATE RESISTANT PROSTATE CANCER
    Michael, Basin F.
    Rebecca, Sager A.
    Hanan, Goldberg
    Joseph, Jacob M.
    Oleg, Shapiro
    Jeffrey, Ross S.
    Alina, Basnet
    Gennady, Bratslavsky
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 : S12 - S12
  • [37] ZEB1 expression is associated with the PTEN loss and TMPRSS2 ERG fusion immune evasion phenotype in prostate cancer.
    Chaves, Luiz P.
    Caliari, Andre L.
    Melo, Camila M.
    Saggioro, Fabiano P.
    Squire, Jeremy A.
    CANCER RESEARCH, 2021, 81 (13)
  • [38] Clinical significance of SCHLAP1:UBE2E3 gene fusion compared to TMPRSS2:ERG gene fusion in localized prostate cancer: Insights from a Korean cohort
    Kang, B.
    Kim, S. H.
    Jang, K. H.
    Seong, W. S.
    Kim, K. H.
    Ha, H. K.
    Lee, C. H.
    Lee, H. S.
    EUROPEAN UROLOGY, 2024, 85 : S1444 - S1445
  • [39] TMPRSS2: ERG gene fusion and epigenetic changes in tumour suppressor genes are associated with clinical markers of poor prognosis in prostate cancer patients
    Jankevicius, F.
    Jarmalaite, S.
    Sabaliauskaite, R.
    Kalinauskaite, N.
    Dasevicius, D.
    Laurinavicius, A.
    Lazutka, J.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (08) : 573 - 573
  • [40] Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2–ERG fusions
    Zachary R. Chalmers
    Michael C. Burns
    Ericka M. Ebot
    Garrett M. Frampton
    Jeffrey S. Ross
    Maha H. A. Hussain
    Sarki A. Abdulkadir
    Prostate Cancer and Prostatic Diseases, 2021, 24 : 558 - 566
12345